Publication:

Pneumonitis, a common adverse event of cyclin-dependent kinase 4/6 inhibitors: a case report

The cyclin-dependent kinase (CDK) 4/6 inhibitors are approved for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, these can develop common adverse events. We present the case of a woman diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer, who developed pneumonitis related to palbociclib. Pulmonary toxicity of CDK 4/6 inhibitors is not an uncommon adverse event that has been increasing in incidence.